Sana Biotechnology

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems

Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday.

Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies

Expect to file IND this year for SC291 with potential clinical data in 2023

Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts have been accepted for presentation, including two oral presentations, at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022 in New Orleans, LA.

Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting

Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates

FibroGen

Heron Therapeutics

ImmunityBio

Nkarta, Inc.

Relay Therapeutics, Inc.

Avidity Biosciences

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

7 Unknown Biotech Stocks That Could Rocket in 2023

SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at September 2022 Investor Conferences

Lemonade

MicroVision

Sientra

Stoke Therapeutics Inc

Tattooed Chef

WeWork

Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-squeeze stocks  in an effort to move the equities higher, forcing the bears to cover their short positions.

7 Stocks Due for a Stunning Short Squeeze

Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology.

Sana Biotechnology A Buy For Potential Cancer Therapies

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented

Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SAN FRANCISCO and SUZHOU, China , June 5, 2022  /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the China National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for Equecabtagene Autoleucel (Innovent R&D code: IBI326，IASO Bio R&D code: CT103A) , a fully human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (R/R MM). Equecabtagene Autoleucel is the first CAR-T therapy in China that is self-developed with proprietary whole-process product development and the first BCMA-targeting CAR T-cell therapy in China with its NDA formally accepted by the NMPA.

Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

After announcing plans last summer to build its manufacturing facility in California, Sana Biotechnology has changed course.

Sana Biotechnology to build manufacturing in Seattle area, switching from California

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive director at the prestigious University of Colorado Gates Institute. Dr. Fry, a world-renowned expert in chimeric antigen receptor T cell (CAR T) therapies, has devoted part of his time to the University of Colorado as a clinical professor of pediatric oncology since joining Sana. He continues to work in his current Sana role without change while serving as the Institute's Executive Director.

Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado's Gates Institute

Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT

Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference at 3:20 p.m. PT on Wednesday, May 11, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts covering preclinical data from its hypoimmune and fusogen platforms were accepted for either oral or poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19, 2022 in Washington, D.C.

Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Plans to present data at multiple scientific conferences in 2022

Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 32nd Annual Oppenheimer Healthcare Conference at 6:20 a.m. PT on Wednesday, March 16, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data from its hypoimmune T cell program will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA.

Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting

Lyell Immunopharma

Sana Biotechnology Inc. ( SANA , Financial) and Lyel Immunopharma Inc. ( LYEL , Financial) are poster children for what's happening in the biotech initial public offering market. The two companies raised a combined total of $1 billion in 2021 and at one point had valuations exceeding a combined $5 billion.

Biotech IPOs Have Slowed to a Snail's Pace

Sana Biotechnology: Exciting Preclinical Science

Pieris Pharma

10X Genomics

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

3 Biotechs That Will Soar Regardless of COVID-19

News for Sana Biotechnology Stock (SANA)